A Phase 2 Study of Azacitidine and Venetoclax Versus a Bone Marrow Transplant in People 65 Years and Older With Acute Myeloid Leukemia

Full Title

A Randomized, Multicenter, Phase II Study of Maintenance Azacitidine and Venetoclax Versus an Allogeneic Stem Cell Transplant in Patients 65 Years and Older with Acute Myeloid Leukemia who Achieve an MRD Negative Complete Remission After Induction with Azacitidine and Venetoclax

Purpose

Researchers are comparing bone marrow transplantation to maintenance chemotherapy as post-induction treatment in older people with acute myeloid leukemia (AML) in remission. The people in this study are 65 or older and already had azacitidine and venetoclax as induction treatment. 

If you take part in this study, you will be randomly assigned to get one of these treatments:

• A bone marrow transplant from a donor
• Maintenance therapy with azacitidine and venetoclax

The researchers want to see if one treatment or the other is better at keeping AML from coming back.

Who Can Join

To join this study, there are a few conditions. You must:

• Have AML in remission following azacitidine and venetoclax and be eligible to receive a bone marrow transplant.
• Have a suitable bone marrow donor.
• Be age 65 or older.

Contact

For more information and to see if you can join this study, please call Dr. Roni Tamari’s office at 646-608-3738.